New research presented at Digestive Disease Week 2024 has highlighted a link between these medications and gastroparesis, showing that patients on GLP-1 drugs are more likely to develop this condition
The Regulatory Environment as Strategic Variable Cost Plus Drugs operates in a regulatory environment that has shifted materially since its launch
Combining retatrutide with other research peptides Some researchers explore whether retatrutide can be part of a broader peptide protocol
After 48 h, 160 l of expression medium (10 g l 1 yeast extract (Gibco, 212750), 20 g l 1 peptone (Gibco, 211677), 20 g l 1 d-galactose (Panreac, A1131), 67 mM potassium phosphate monobasic buffer pH 6.0 (Thermo Scientific, 424200250), 25 g l 1 ethanol (Scharlau, ET00062500), 2 mM copper sulfate (Merck, C7631) and 25 g ml 1 chloramphenicol (Merck, C0378)) was added to each well
Explore the impact of rising GLP-1 costs on employer health benefits